|
|
Blood, Vol. 110, Issue 2, 616-623, July 15, 2007
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma
Blood Polson et al.
110: 616
Supplemental materials for Polson et al, Vol. 110, Issue 2, 616-623
Files in this Data Supplement:
- Figure S1. Immunofluorescent staining of xenograft tumors treated with ADCs (PDF, 7.31 MB) -
Immunofluorescent staining for hIgM (green) and mIgG (red) in untreated (top row), anti-gp120-MCC-DM1 treated (middle row) and anti-CD79b(SN8)-MCC-DM1 treated BJAB-luc xenografts. In untreated xenografts, hIgM was localized to the plasma membrane of BJABluc cells and there was no specific mIgG labeling above background. Nuclei labeled with DAPI (blue) appear intact. In anti-gp120-MCC-DM1 treated xenografts, hIgM was also localized to the membrane, while mIgG was detected in the extracellular space and stromal compartments of the tumor. In anti-CD79b(SN8)-MCC-DM1 treated xenografts, very few hIgM positive cells were present, and these did not show the typical plasma membrane staining pattern. In some cells, hIgM and mIgG were colocalized within the cytoplasm of BJAB-luc cells, a pattern that is consistent with the binding of anti-CD79b(SN8)-MCC-DM1 to the BCR complex and subsequent internalization of the antibody drug conjugate bound to receptor. Note the extensive loss and fragmentation of nuclei, indicative of the cytotoxic activity of the anti-CD79b(SN8)-MCC-DM1 conjugate.
- Figure S2. LAMP1 demarcates the MIIC (PDF, 1.45 MB) -
Ramos cells were fixed and permeabilized as described in “Internalization studies, Materials and methods” and costained for the MIIC marker HLA-DM (red channel, A,C) and the late endosome/lysosomal marker LAMP1 (green channel, B,C). The HLA-DM staining completely overlapped with that of LAMP1, but was much weaker and so less evident in the overlay. Similar results were obtained in BJAB and Daudi cells (data not shown). Scale bar = 20 µM
| |
